基于人口的研究,研究了德国主要转移性肺癌患者的生存进展
Therese Tzschoppe1, Julia Ohlinger1, Dirk Vordermark1
1Department of Radiation Oncology, Health Services Research Group, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.
Scientific reports
|July 11, 2024
概括
新的肺癌治疗方法,包括化疗和免疫疗法,正在改善转移性非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC) 患者的生存率. 放射治疗对SCLC的好处比NSCLC更大.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 肺癌的死亡率很高,经常在转移阶段被诊断出来.
- 了解治疗对转移性肺癌存活率的影响至关重要.
研究的目的:
- 评估新治疗策略对转移性肺癌存活率的影响.
- 将非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC) 的结果进行比较.
主要方法:
- 利用来自德国 (2007-2018) 的基于人口的数据.
- 分析了使用卡普兰-梅尔方法和多变量危险比率的生存率.
- 对NSCLC和SCLC以及按性别进行差异化分析.
主要成果:
- 随着时间的推移,观察到生存率的适度增加.
- 化疗改善了所有患者的生存率.
- 放射治疗对SCLC患者有好处;对NSCLC患者的好处很小.
- 免疫疗法增加了NSCLC患者的存活率.
结论:
- 放射治疗,化疗和免疫治疗的进步提高了转移性NSCLC和SCLC的存活率.
- 治疗方式的有效性在NSCLC和SCLC亚型之间有所不同.
相关概念视频
Cancer Survival Analysis
340
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
340
Kaplan-Meier Approach
123
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
123


